Download Files:
Onvansertib
$80 – $490
Products Details
Product Description
– NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM.
Web ID
– HY-15828
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C24H27F3N8O3
References
– [1]Beria I, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74.|[2]Valsasina B, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16.|[3]Casolaro A, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3):e58424.
CAS Number
– 1034616-18-6
Molecular Weight
– 532.52
Compound Purity
– 99.55
SMILES
– O=C(C1=NN(CCO)C2=C1CCC3=CN=C(NC4=CC(N5CCN(C)CC5)=CC=C4OC(F)(F)F)N=C23)N
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 21 mg/mL (ultrasonic;warming)
Target
– Apoptosis;Polo-like Kinase (PLK)
Isoform
– PLK1
Pathway
– Apoptosis;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
